INTRODUCTION
============

Epilepsy, one of the most common serious neurological disorders, is characterized by the unpredictable occurrence of seizures. A seizure is an abnormal electrical discharge in the brain that causes an alteration in consciousness, sensations, and behaviors. The symptoms that occur depend on the parts of the brain affected during the seizure. Common signs of seizures include staring, unusual feelings, twitching, unconsciousness, and jerking in the arms or legs. Epilepsy affects an estimated 3 million Americans and about 65 million people worldwide in a variety of ways ([@B97]; [@B88]). About 150,000 new cases of epilepsy are diagnosed in the United States annually ([@B88]). Children and adults are the fastest-growing segments of the population with new cases of epilepsy.

Epilepsy is a collective designation for a group of brain disorders consisting of a complex spectrum of different seizure types and syndromes. Epileptic seizures are classified into partial (simple and complex partial seizures) and generalized seizures (absence, tonic--clonic, myoclonic, and atonic seizures). Accurate diagnosis of seizure type and epileptic syndrome is critical for determining appropriate drug therapy and prognosis. The International League Against Epilepsy (ILAE) provided a definition of "seizure" and "epilepsy" ([@B53]). A seizure is defined as "a transient occurrence of signs and/or symptoms due to abnormal synchronous neuronal activity in the brain." Epilepsy is defined as "a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures." A single seizure, therefore, does not constitute epilepsy. The diagnosis of epilepsy requires the occurrence of recurrent (two or more) epileptic seizures separated by at least 24 h, unprovoked by any immediate identified cause. Antiepileptic drugs (AEDs) are the mainstay for controlling seizures (**Table [1](#T1){ref-type="table"}**). Current drug therapy is symptomatic in that available drugs inhibit seizures, but neither effective prophylaxis nor cure are available. The goal of the therapy is to eliminate seizures without interfering with normal function ([@B64], [@B65]). Despite many advances in epilepsy research, presently an estimated 30% of people with epilepsy have "intractable seizures" that do not respond to even the best available medication. There is renewed focus on the pathophysiology of epileptogenesis, the process whereby a brain becomes progressively epileptic due to an initial precipitating event.

###### 

List of current antiepileptic drugs.

  Standard (first generation)    Newer (second generation)
  ------------------------------ ---------------------------
  Carbamazepine (Tegretol)       Acetazolamide (Diamox)
  Clonazepam (Klonopin)          Clobazam (Onfi)
  Chlorazepate (Tranxene)        Ezogabine (Potiga)
  Diazepam (Valium)              Felbamate (Felbatol)
  Divalproex sodium (Depakote)   Fosphenytoin (Cerebyx)
  Ethosuximide (Zarontin)        Lacosamide (Vimpat)
  Ethotoin (Peganone)            Lamotrigine (Lamictal)
  Lorazepam (Ativan)             Levetiracetam (Keppra)
  Mephobarbital (Mebaral)        Oxcarbazepine (Trileptal)
  Methsuximide (Celontin)        Parampanel (Fycompa)
  Nitrazepam (Mogadon)           Pregabalin (Lyrica)
  Phenobarbital (Gardinal)       Progabide (Gabrene)
  Phenytoin (Dilantin)           Rufinamide (Banzel)
  Primidone (Mysoline)           Tiagabine (Gabitril)
  Valproic acid (Depakene)       Topiramate (Topamax)
                                 Vigabatrin (Sabril)
                                 Zonisamide (Zonegran)

This article describes the emerging evidence of hormonal influence on epileptogenesis and the potential mechanisms underlying their actions on neuronal excitability and seizure activity. It also describes recent studies on neurosteroid agents that prevent or delay the development of epilepsy. The main focus of the review is on steroid hormones and neurosteroids with seizure-modulating activity. Neuropeptides and other hormones such as oxytocin, neuropeptide-Y, and galanin, which may affect neuronal excitability, are not discussed here because such description is beyond the scope of this article. The seizure-modulating effects of neuropeptides are discussed elsewhere ([@B191]).

OVERVIEW OF EPILEPTOGENESIS AND INTERVENTION STRATEGIES
=======================================================

Epilepsy is a chronic condition with many possible causes. Epilepsy may develop because of an abnormality in neural connectivity, an imbalance in inhibitory and excitatory neurotransmitters, or some combination of these factors. Primary epilepsy (50%) is idiopathic ("unknown cause"). In secondary epilepsy (50%), seizures may result from a variety of conditions including trauma, anoxia, metabolic imbalances, tumors, encephalitis, drug withdrawal, and neurotoxicity ([@B52]). The molecular mechanisms underlying the development of acquired epilepsy are not very well understood. The term "epileptogenesis" is used to describe the complex plastic changes in the brain that, following a precipitating event, convert a normal brain into a brain debilitated by recurrent seizures ([@B153]; [@B154]). Although specific types of epilepsy may have unique pathophysiological mechanisms, a broad hypothesis in this field is that convergent neuronal mechanisms are common in different forms of acquired epilepsy.

The current hypothesis about the pathogenesis of epilepsy (epileptogenesis) involves three stages: (1) the initial precipitating event; (2) the latent period (no seizures); and (3) the chronic period with spontaneous seizures (**Figure [1](#F1){ref-type="fig"}**). Acquired epilepsy typically develops due to an initial precipitating event such as traumatic brain injury (TBI), stroke, brain infections, or prolonged seizures. The other possible precipitating triggers for epileptogenesis include febrile seizures, metabolic dysfunction, alcohol withdrawal, and status epilepticus, an emergency condition characterized by continuous seizures or repeated seizures without regaining consciousness for 30 min or more ([@B131]). Exposure to organophosphorous pesticides and chemical warfare nerve agents, such as soman, can cause epilepsy as a result of cholinergic neurotoxicity and status epilepticus ([@B41]).

![**Pathophysiology of epileptogenesis.** Epileptogenesis is the process whereby a normal brain becomes progressively epileptic because of precipitating injury or risk factors such as TBI, stroke, brain infections, or prolonged seizures. Epilepsy development can be described in three stages: (1) the initial injury (epileptogenic event); (2) the latent period (silent period with no seizure activity); and (3) chronic period with spontaneous recurrent seizures. Although the precise mechanisms underlying spatial and temporal events remain unclear, epileptogenesis may involve an interaction of acute and delayed anatomic, molecular, and physiological events that are both complex and multifaceted. The initial precipitating factor activates diverse signaling events, such as inflammation, oxidation, apoptosis, neurogenesis, and synaptic plasticity, which eventually lead to structural and functional changes in neurons. These changes are eventually manifested as abnormal hyperexcitability and spontaneous seizures.](fncel-07-00115-g001){#F1}

The development of epileptogenesis is thought to be a step-function of time after the brain injury, with a latent period present between the brain injury and the first unprovoked seizure. There are some alternative hypotheses to this notion that view epileptogenesis as a continuous process that extends past the first spontaneous seizure ([@B46]). Temporal lobe epilepsy (TLE) is one of the common forms of chronic epilepsies ([@B241]). TLE is characterized by the progressive expansion of spontaneous seizures originating from the limbic system regions, especially the hippocampus, most often due to neuronal injury. The hippocampal sclerosis, which is characterized by aberrant mossy fiber sprouting and widespread neuronal loss in the dentate hilus and CA1 and CA3 subfields, is the hallmark of epilepsy pathology ([@B221]; [@B28]; [@B143]; [@B139]). However, there is an ongoing debate about whether the hippocampal sclerosis is the basis or the outcome of recurring seizures. There is emerging evidence from refractory models that epilepsy involves "progressive epileptogenesis" much beyond the latent period and the onset of the first seizure ([@B242]). Several mechanisms have been described including loss of interneurons ([@B229]; [@B210]) and neuroinflammation ([@B237]). There is great variation in the onset of spontaneous seizures following a precipitating factor ([@B160]; [@B144]). Thus, the critical window for effective "antiepileptogenic" interventions remain poorly defined for curing epilepsy in people at risk.

Studies in animal models have provided improved understanding of neurophysiological basis of epileptic seizures ([@B146]; [@B208]). Spontaneous seizures arise from hyperexcitable and hypersynchronous neuronal networks and involve both cortical and several key subcortical structures. The general cellular pathway underlying occurrence of epileptic seizures is apparent in three phases: (i) focal epileptogenicity (initiation); (ii) synchronization of the surrounding neurons (sync); and (iii) propagation of the seizure discharge to other areas of the brain (spread). Experimental field and intracellular recordings in isolated brain sections provide a detailed description of neurophysiological abnormalities underlying epileptic regions. Paroxysmal depolarization shift (PDS) is identified as a hallmark of epileptic neurons. It is characteristic of neurons in epileptic cortical zones and consists of an abnormally prolonged depolarization with repetitive spiking reflected as interictal discharges in the electroencephalogram (EEG). High-frequency oscillations, termed ripples (80--200 Hz) and fast ripples (250--600 Hz), are recorded in the EEG of epileptic patients and in animal epilepsy models ([@B108]; [@B119]). Fast ripples are thought to reflect pathological activity and seizure onset zones.

[@B68] proposed that *seizures beget seizures*. The kindling model has provided a conceptual framework for this idea and for developing new molecular targets for preventing epilepsy ([@B67]; [@B133]). Post-status epilepticus paradigms are widely used for modeling the epileptogenesis in which a single episode of prolonged seizures (by pilocarpine, kainate, or electrical stimulation) triggers progressive development of seizure activity ([@B27]; [@B79]; [@B66]; [@B160]; [@B123]). These chronic models share many features of human limbic epilepsy ([@B122]; [@B213]). Pilocarpine, kainate, or perforant path stimulation induce acute SE and neuronal injury and follow a pattern of latent period similar to that observed in limbic epilepsy. Like TLE, mossy fiber sprouting, neurodegeneration, and ectopic granule cell proliferation are evident after the latent period ([@B122]; [@B160]).

Despite decades of research, currently there is no single Food and Drug Administration (FDA)-approved drug that truly prevents the development of epilepsy in people at risk. A variety of intervention approaches have been tested in animal models of epileptogenesis ([@B1]; [@B154]). A number of clinical trials show a lack of antiepileptogenic efficacy of AEDs, including phenytoin and carbamazepine, in patients at high risk for developing epilepsy ([@B222]; [@B130]). There is a desperate need for drugs that truly prevent the development of epilepsy ("antiepileptogenic agents") or alter its natural course to delay the appearance or severity of epileptic seizures ("disease-modifying agents").

In 2000, National Institute of Neurological Disorders and Stroke (NINDS) and epilepsy research and advocacy groups organized the first "Curing Epilepsy" conference, which marked a turning point for shifting and expanding the focus of epilepsy research toward cures for epilepsy and the prevention of epilepsy in those at risk ([@B96]). During the past decade, there has been increasing research emphasis on the prevention of epileptogenesis and translation of lead discoveries in this field into therapies for curing epilepsy ([@B97]; [@B208]). The Institute of Medicine (IOM) released a consensus report in 2012 on public health dimensions of the epilepsies focusing on promoting health and understanding epilepsy ([@B10]; [@B88]). The IOM report, *Epilepsy Across the Spectrum: Promoting Health and Understanding*, provided 13 recommendations for future work in the field of epilepsy. The report contains research priorities which include one key recommendation on prevention of epilepsy.

ROLE OF STEROID HORMONES IN EPILEPTOGENESIS
===========================================

Steroid hormones play a key role in the neuroendocrine control of neuronal excitability and seizure susceptibility (**Table [2](#T2){ref-type="table"}**; [@B83]; [@B161], [@B169]; [@B235]). Steroid hormones are synthesized and secreted from ovarian, gonadal, and adrenal sources. In men, the main circulating steroids are androgenic steroids (testosterone and dihydrotestosterone) and adrenal corticosteroids (cortisol and aldosterone). Deoxycorticosterone (DOC) is also released from adrenal cortex in response to stress. In women, the primary reproductive steroid hormones are estrogens and progesterone, which are released during the menstrual cycle. The early follicular phase is associated with low levels of estrogens and progesterone. The synthesis and secretion of estrogens and progesterone from the ovaries are controlled primarily by hypothalamic gonadotropin releasing hormone (GnRH) and the pituitary gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH). As ovulation approaches, the level of estrogen rises and triggers a large surge of LH leading to ovulation. Following ovulation, the ruptured follicle luteinizes and forms a corpus luteum that secretes progesterone and estrogen. Estradiol is secreted in the second half of the follicular phase and increases to a peak at midcycle, while progesterone is elevated during the luteal phase and declines before menstruation begins.

###### 

List of steroid hormones and neurosteroids that affect seizure susceptibility.

  Anticonvulsant steroids             Proconvulsant steroids
  ----------------------------------- ------------------------
  Progesterone                        Estradiol
  Allopregnanolone                    Pregnenolone sulfate
  Pregnanolone                        DHEA sulfate
  Dihydroprogesterone                 Cortisol
  Androstanediol                      11-Deoxycortisol
  Etiocholanone                       
  Dihydrotestosterone                 
  Deoxycorticosterone                 
  Dihydrodeoxycorticosterone          
  Allotetrahydrodeoxycorticosterone   

The cyclical changes of estrogens and progesterone are now widely believed to be important in the pathogenesis of catamenial epilepsy, a menstrual cycle-related seizure disorder in women with epilepsy ([@B167], [@B171]). Catamenial epilepsy is a multifaceted neuroendocrine condition in which seizures are clustered around specific points in the menstrual cycle, most often around perimenstrual or periovulatory period. Generally, estrogens are found to be excitatory or proconvulsant, while progesterone has powerful antiseizure effect and reduces seizures, and thus they play a central role in the pathophysiology of epilepsy in women ([@B167], [@B171]). Progesterone is an intermediate precursor for the synthesis of neurosteroids, which are increased in parallel during the ovarian cycle. There is emerging evidence that endogenous neurosteroids influence seizure susceptibility and epileptogenesis ([@B170]; [@B187]).

PROGESTERONE
------------

Progesterone is an endogenous anticonvulsant hormone with substantial impact on seizure susceptibility. The potential molecular pathways for the progesterone modulation of seizure activity are illustrated in **Figure [2](#F2){ref-type="fig"}**. Progesterone is an appealing hormone for prophylactic interventions on epilepsy development, due to its multifunctional modulatory actions in the brain. Progesterone has long been known to have antiseizure activity in animal models ([@B205]; [@B37]; [@B109]; [@B60]; [@B172]), and in clinical studies ([@B13]; [@B81], [@B82]). Women with epilepsy are prone to seizures in response to decreased levels of progesterone during perimenstrual periods ([@B87]; [@B167]). Indeed, the incidence of epilepsy is generally lower in women than in men ([@B77]; [@B33]; [@B132]). This gender difference could be caused by ovarian hormones such as progesterone. Although progesterone is known to inhibit stimulation-evoked seizures in kindling models ([@B90]; [@B138]; [@B121]), it has not been investigated widely for potential disease-modifying effect in epileptogenic models. In the kindling model, progesterone has been shown to impair or retard epileptogenesis ([@B90]; [@B50]; [@B173]).

![**Biosynthesis and targets of steroid hormones and neurosteroids in the brain.** Enzymatic pathways for the production of three prototype neurosteroids allopregnanolone, THDOC, and androstanediol are illustrated from cholesterol. Steroid hormones progesterone, deoxycorticosterone, and testosterone undergo two sequential A-ring reduction steps catalyzed by 5α-reductase and 3α-HSOR to form the 5α,3α-reduced neurosteroids. The conversion of intermediate precursor steroids into neurosteroids occurs in the hippocampus and several other regions within the brain, where they can affect neuronal function. As evident from the pathways, many modifications are made by the same enzymes, which can be blocked by specific inhibitors (trilostane, finasteride, and indomethacin). There are two mechanisms by which steroid hormones affects neuronal function: (i) binding to steroid receptors (PRs, ARs, or MRs; left panel) and (ii) conversion to GABA-A receptor-modulating neurosteroids (right panel). Progesterone, deoxycorticosterone, or testosterone binding to their cognate steroid receptors could lead to activation of gene expression in the brain. Neurosteroids rapidly modulate neuronal excitability by direct interaction with inhibitory GABA-A receptors in the brain.](fncel-07-00115-g002){#F2}

Recently progesterone has been evaluated in an National Institutes of Health (NIH)-sponsored, multicenter clinical trial as a treatment for epilepsy in women ([@B84]). This randomized, double-blind, placebo-controlled, phase III, multicenter, clinical trial compared the efficacy and safety of adjunctive cyclic natural progesterone therapy versus placebo treatment of intractable seizures in 294 subjects randomized 2:1 to progesterone or placebo, stratified by catamenial and non-catamenial status. The results indicate lack of significant difference in proportions of responders between progesterone and placebo groups. However, a more restricted analysis on a subset of the data found a significantly higher responder rate in women with perimenstrual seizure exacerbation. These findings suggest that progesterone may provide a clinically important benefit for a subset of women with perimenstrual catamenial epilepsy. The dramatic response to progesterone, which is a neurosteroid precursor, in women with perimenstrual catamenial epilepsy is attributable to the unique neurosteroid sensitivity of perimenstrual catamenial seizures ([@B167]).

Previous studies have shown that progesterone supports the normal development of neurons, and that it reduces the extent of brain damage after TBI ([@B192]; [@B215]). It has been observed in animal models that females have reduced susceptibility to TBI and this protective effect has been hypothesized to be caused by increased circulating levels of progesterone in females ([@B193]; [@B134]). A number of additional studies have confirmed that progesterone has neuroprotective effects ([@B63]; [@B209]). Promising results have also been reported in human clinical trials. Recently, two clinical studies have evaluated progesterone as a treatment for moderate to severe TBI ([@B246]; [@B248]). These studies demonstrated the efficacy of progesterone as a neuroprotective agent in TBI. Progesterone is highly efficacious in reducing disability and death in TBI. Progesterone has neuroprotective properties in acute models of ischemic injury, stroke, and astroglial dysfunction ([@B107]; [@B99]; [@B78]), suggesting its beneficial effects in brain injury.

Progesterone targets multiple molecular and cellular mechanisms relevant to epileptogenesis, and may therefore be a natural disease-modifying agent. Progesterone's cellular actions are mediated by the progesterone receptors (PRs), which are expressed in the hypothalamus, neocortex, hippocampus, and limbic areas ([@B26]). Progesterone is an intermediate precursor for the synthesis of neurosteroids (see Role of Neurosteroids in Epileptogenesis). Progesterone's antiseizure activity is mediated mainly by its conversion to allopregnanolone, a neurosteroid and positive modulator of GABA-A receptors with broad-spectrum antiseizure properties ([@B18]; [@B109]; [@B59]; [@B104]; [@B172]). Moreover, neurosteroids can modulate PRs via intracellular metabolism to analogs that bind to PRs ([@B197]). Progesterone may modulate signaling cascades of inflammation, apoptosis, neurogenesis, and synaptic plasticity ([@B148]; [@B236]; [@B216]), and therefore, progesterone may directly exert disease-modifying effects on epileptogenesis.

Recently, progesterone has been tested in rodent models of hippocampus epileptogenesis ([@B173]; [@B179]; [@B181]). At low, non-sedative doses, progesterone treatment for 2 weeks significantly suppressed the rate of development of kindled seizure activity evoked by daily hippocampus stimulation in mice, indicating a disease-modifying effect of progesterone on limbic epileptogenesis. There was a significant increase in the rate of "rebound or withdrawal" kindling during drug-free stimulation sessions following abrupt discontinuation of progesterone treatment. A washout period after termination of progesterone treatment prevented such acceleration in kindling. The molecular mechanisms underlying progesterone's attenuating effect on kindling development remains unknown. There are several potential mechanisms by which progesterone could inhibit epileptogenesis, including activation of PRs, synthesis of neurosteroids, modulation of oxidative cascades, and promoting neuroprotection. The effect of progesterone on the early kindling progression is reduced in mice lacking PRs, which provide evidence that PRs may be partly involved in progesterone's disease-modifying effects ([@B173]). These findings are consistent with the role of PRs in progesterone inhibition of epileptiform activity in the hippocampus ([@B49]). Despite the early attenuation, late stage kindling progressed normally in the PRKO mice, suggesting that PRs are not involved in the later part of the kindling progression. However, the extent to which PRs mediate the progesterone's disease-modifying effect remains unclear. Collectively, the disease-modifying effect of progesterone may occur through a complex mechanism partly involving PR-dependent and PR-independent pathways.

Progesterone is rapidly metabolized into neurosteroids pregnanolone and allopregnanolone, which could mediate progesterone's attenuating effects on kindling epileptogenesis. This possibility is supported by emerging evidence that neurosteroids can retard the development of spontaneous seizures in post-SE models of epileptogenesis ([@B20], [@B21]). It is suggested that 5α-reductase converts progesterone to allopregnanolone and related neurosteroids that retard epileptogenesis. To further test this hypothesis, we utilized the mouse hippocampus kindling model of epileptogenesis and investigated the effect of finasteride, a 5α-reductase and neurosteroid synthesis inhibitor ([@B181]). In a kindling model in adult mice, pre-treatment with finasteride significantly blocked progesterone's inhibition of epileptogenesis ([@B179]), and led to complete inhibition of the progesterone-induced retardation of limbic epileptogenesis in mice ([@B181]). Therefore, neurosteroids such as allopregnanolone may mediate the disease-modifying effect of progesterone in the kindling model (see Role of Neurosteroids in Epileptogenesis).

In addition, progesterone's modulation of inflammation is suggested as an appealing mechanism because pro-inflammatory molecules and oxidative signaling has been found to be activated in animal models of epilepsy ([@B148]; [@B236]). Progesterone has pleiotropic effects on inflammation and cell growth/survival ([@B78]; [@B216]) that may contribute to its attenuating effects on epileptogenesis. Progesterone inhibits secreted phospholipase A2 enzyme, a very high level target in the inflammatory cascade that has been shown to induce neurodegeneration through glutamate release ([@B42]; [@B249]). Progesterone has been shown in numerous preclinical models to be neuroprotective after injury ([@B192]; [@B107]; [@B99]; [@B39]). Recently, two clinical studies have evaluated progesterone as a treatment for moderate to severe TBI ([@B246]; [@B248]). The progesterone was administered over a period of 3 or 5 days beginning within 8 or 11 h of the injury. In both studies, the groups receiving progesterone had significantly fewer deaths than those receiving placebo. In addition, there was evidence of improved functional outcomes in the progesterone-treated groups, suggesting that progesterone is highly efficacious in reducing morbidity and mortality in TBI, which is a leading cause of epilepsy in adults and military persons.

TESTOSTERONE
------------

Testosterone has marked impact on seizure susceptibility. The potential biosynthetic pathways of testosterone metabolism are illustrated in **Figure [2](#F2){ref-type="fig"}**. Testosterone is known to produce both proconvulsant and anticonvulsant effects depending on the animal model and the seizure type ([@B166]). Both animal and clinical studies show that testosterone enhances seizure activity by metabolism to estrogens ([@B95]; [@B225]; [@B86]; [@B48]; [@B51]). Epidemiological data indicate that the occurrence of focal and tonic--clonic epileptic seizures is \~50% higher in intact than in castrated dogs ([@B238]). On the contrary, testosterone and related androgens have protective effects against seizures induced by pentylenetetrazol and kainic acid ([@B203]; [@B56]; [@B57],[@B58]; [@B164]). Moreover, studies in orchidectomized or castrated animals have shown that decreased testosterone is associated with higher incidence of seizures and replacement with testosterone attenuates seizures ([@B70]; [@B224]; [@B151]; [@B152]). It is demonstrated that testosterone modulation of seizure susceptibility occurs through its conversion to neurosteroids with "anticonvulsant" and "proconvulsant" actions, and hence the net effect of testosterone on neural excitability and seizure activity depends on the levels of distinct testosterone metabolites within the brain ([@B163],[@B164]). Unlike estradiol, which generally facilitates seizures ([@B12]; [@B91]; [@B29]; [@B245]), androstanediol has been shown to produce powerful antiseizure effects ([@B164]; [@B105]). Testosterone might have a biphasic effect on seizures: proconvulsant at higher doses, anticonvulsant at lower doses. However, testosterone itself has not been reported to improve seizures clinically ([@B86]). Reductions of seizures were observed only when testosterone was given together with an estrogen synthesis inhibitor ([@B86]), suggesting the estradiol modulation of seizure activity.

In many men with epilepsy, testosterone deficiency is an unusually common clinical observation ([@B125]; [@B80]; [@B51]). TLE surgery has been shown to reduce seizure occurrence and normalize serum androgen concentrations in men with epilepsy ([@B16]). Alterations in testosterone levels, therefore, may possibly contribute to exacerbation of seizures. The introduction of finasteride (*Propecia*), which inhibits dihydrotestosterone and androstanediol synthesis, for the treatment of male pattern baldness led to recurrent seizures, which then subsided once the drug was discontinued. Finasteride-induced seizure exacerbation has also been reported recently ([@B85]). There is a new case report implicating endogenous neurosteroids in TLE ([@B155]). Two-week phenytoin treatment has been shown to affect the hippocampal levels of testosterone, cytochrome P450 (CYP) isoforms, and androgen receptor (AR) expression ([@B135]). The increased metabolism of testosterone leading to augmented androgen metabolite formation most likely led to enhanced expression of CYP19 and AR in hippocampus, which is a critical area for limbic epileptogenesis.

Aromatase is the key enzyme for the conversion of testosterone to estradiol, a neuroactive steroid that promotes seizures. Aromatase is expressed in discrete areas in the brain such as hippocampus and neocortex that are involved in epileptogenesis. Aromatase inhibitors could decrease brain excitability by decreasing local estradiol levels and therefore, could be beneficial for the treatment of epilepsy ([@B124]). Consequently, aromatase inhibitors have been proposed as a suitable approach to seizure therapy in some men with epilepsy. Some aromatase inhibitors have been tested in men with epilepsy: testolactone, letrozole, and anastrozole. [@B86] tested the efficacy of testosterone and testolactone in men with intractable complex partial seizures. Improvement in seizure control was reportedly achieved with testosterone therapy when testosterone was used along with testolactone. In a case report, letrozole has been shown to improve seizure control in a 61-year-old man with epilepsy ([@B72], [@B73]). In a pilot study, the safety and efficacy of add-on anastrozole therapy was tested in men with intractable epilepsy. Men with the greatest seizure reduction showed unexpectedly elevated levels in FSH, a pituitary-derived gonadotropin. Hence, the outcome of trials with three distinct aromatase inhibitors -- testolactone, letrozole, and anastrozole -- suggests a beneficial treatment modality for men with epilepsy ([@B73]). Therefore, it is likely that aromatase inhibitors could be potential agents for interruption of proepileptogenic estrogens in the brain.

ESTROGENS
---------

Although estrogens can affect seizure susceptibility, the role of various estrogens in epileptogenesis is poorly understood. In general, estrogens have proconvulsant and epileptogenic properties in animals and humans ([@B201]). There are limited studies that support protective effects of estrogens, but it may act as a anticonvulsant under some conditions ([@B230]). Estradiol has been widely investigated in animal epilepsy models. The effect of estrogens on seizure susceptibility is highly variable and depends on factors such as treatment duration, dosage, hormonal status, and the seizure model ([@B233]). Early studies of estradiol administration to ovariectomized rats revealed proconvulsant effects ([@B167]). The effect of estrogens on hippocampus seizure susceptibility is controversial ([@B201]). While estradiol has been shown to be proconvulsant in several studies, there is also evidence that support lack of effect or protective effect of estrogens ([@B189]; [@B234]; [@B233]). The effect of circulating estrogens has been studied in female rats with epilepsy ([@B200], [@B202]). Epileptic female rats show cyclic increases in epileptiform activity in EEG recordings that coincide with their ovarian cycle, mostly attributable to estrogens.

Estradiol has been known to play a role in the exacerbation of seizures in women with epilepsy ([@B120]; [@B12]; [@B98]). Plasma estradiol levels are found to increase during both the follicular and luteal phase of the normal menstrual cycle. [@B12] was the first investigator to characterize the relationship between seizures and steroid hormones. In women with epilepsy, a positive correlation between seizure susceptibility and the estrogen-to-progesterone ratio was observed, peaking in the premenstrual and preovulatory periods and declining during the midluteal phase. [@B120] have demonstrated that intravenous infusions of estrogen were associated with rapid interictal epileptiform activity in women with epilepsy, and seizures were exacerbated when estrogen was given premenstrually. Therefore, it is hypothesized that estrogens may facilitate some forms of catamenial seizures observed during these phases. The periovulatory catamenial exacerbation has been attributed to the midcycle surge of estrogen that is relatively unopposed by progesterone until early luteal phase ([@B120]). An increase in the ratio of estrogen-to-progesterone levels during perimenstrual period might at least partly contribute to the development of perimenstrual catamenial epilepsy ([@B24]; [@B87]). A recent report from the Nurses' health study in 114,847 nurses identified key factors associated with seizures in women with epilepsy ([@B47]). Menstrual irregularity at ages 18--22 years was specifically associated with an increased risk of epilepsy. Menstrual irregularity during follow-up and early age at menarche increased the risk of isolated seizures. Oral contraceptive uses are not associated with isolated seizure or epilepsy.

GLUCOCORTICOIDS
---------------

Pituitary--adrenal hormones have long been known to affect epileptogenesis ([@B4]; [@B194]; [@B239]; [@B101]; [@B25]). Acute stress raises seizure threshold in animals, but chronic stress is known to be a clear risk factor for precipitating seizures in patients with epilepsies. Stress increases plasma and brain concentrations of corticosteroids and neurosteroids. Acute physical or psychological stress causes increased production of hypothalamic corticotrophin releasing hormone (CRH), which is transported via hypophyseal portal system to the pituitary, where it increases both adrenocorticotropic hormone (ACTH) synthesis and secretion. Major physiological effects result from ACTH's action on adrenal cortex to increase the circulating levels of corticosteroids, principally the glucocorticoid cortisol, and the mineralocorticoid DOC. Cortisol is a major corticosteroid secreted from the adrenal cortex. Cortisol is an excitatory steroid. It elicits proconvulsant and epileptogenic effects ([@B190]; [@B100]). DOC elicits inhibitory effects and protects against seizures ([@B162]). An imbalance in cortisol and DOC and other corticosteroids may contribute to susceptibility or resistance to epileptogenesis.

Stress enhances epileptogenesis. In general, chronic or repeated stress has been shown to enhance vulnerability to epileptogenesis in animal models ([@B101]). Corticosterone, the major adrenal steroid in rodents, has been tested extensively in animal models ([@B239]; [@B114], [@B115]; [@B101]; [@B25]; [@B43]). Prolonged exposure to elevated corticosterone, used as a model of chronic stress, accelerates limbic epileptogenesis ([@B114]). Exposure to repeated experimental stress accelerates the development of limbic epileptogenesis, an effect which may be related to elevated corticosterone levels ([@B102]). Chronic low-dose corticosterone supplementation is shown to enhance epileptogenesis in the rat amygdala kindling model ([@B114]). Episodic corticosterone treatment elicits a striking acceleration in kindling epileptogenesis and triggers long-term changes in hippocampal CA1 neurons ([@B106]). Overall, corticosterone -- with other stress hormones -- rapidly enhances CA1/CA3 hippocampal activity shortly after stress and could imposes a risk for neuronal injury, such as during epileptic activity. In the hippocampus, stress-induced elevations in neurosteroids promote inhibitory tone mediated through GABA-A receptors. Under conditions of repetitive stress, hormonal influences on the inhibitory tone might diminish and instead, increased excitation become more apparent. In agreement, perinatal stress and elevated corticosteroid levels accelerate epileptogenesis and lower seizure threshold in rodent epilepsy models ([@B199]; [@B116]; [@B43]). Therefore, exposure to stressful events during a critical phase in epileptogenesis could impose lasting deleterious effects on the course of epilepsy.

Deoxycorticosterone, a mineralocorticoid precursor with anesthetic and antiseizure properties, is also produced in the adrenal zona fasciculate. Although the antiseizure properties of DOC in human were first described in 1944 ([@B3]; [@B4]), the mechanisms underlying the brain actions of DOC were only recently identified. The antiseizure activity of DOC requires its enzymatic conversion to 3α,21-dihydroxy-5α-pregnan-20-one (THDOC), a neurosteroid that is a powerful positive allosteric modulator of GABA-A receptors ([@B162]; **Figure [2](#F2){ref-type="fig"}**). THDOC is released during physiological stress nearly exclusively from adrenal sources ([@B156]; [@B162]). Plasma and brain levels of THDOC rise rapidly following acute stress ([@B157]; [@B36]; [@B184]). Acute stressors such as swimming, foot shock, or carbon dioxide exposure elicit an increase in allopregnanolone and THDOC concentrations in plasma and in brain ([@B14], [@B15]; [@B228]). Stress-induced THDOC and neurosteroids have been demonstrated to elevate seizure threshold ([@B184]) and contributes to neuroprotection ([@B162], [@B165]).

11-Deoxycortisol (pregn-4-ene-17,21-diol-3,20-dione; DC) is an immediate precursor of cortisol. DC acts as a competitive antagonist of glucocorticoid receptor *in vitro*, but is ineffective as a glucocorticoid antagonist *in vivo* due to adrenal 11-hydroxylation ([@B38]). Nearly 50 years ago, [@B89] observed that systemic administration of large doses of DC succinate induces long-lasting seizure activity in rats and cats. The mechanism underlying pro-epileptic properties of DC has been studied recently ([@B103]). DC is capable of inducing long-lasting status epilepticus in rodents that is refractory to several anticonvulsant drugs. In electrophysiological studies, DC is shown to accelerate the decay time of the inhibitory post-synaptic currents mediated by GABA-A receptors in brain slices, indicating that it significantly impedes GABAergic inhibition which may lead to paroxysmal epileptiform network activity and convulsive seizures. Because DC is an endogenous substance, it is suggested to contribute to an increased seizure propensity in some clinical situations. However, the specific role of DC to the pathophysiology of epileptogenesis is remains unclear.

Physical activity has been suggested as a positive disease-modifying factor for preventing or delaying the development of epilepsy. Exercise has beneficial effects on epileptogenesis ([@B6], [@B8], [@B7]; [@B207]). Exercise treatment reduced brain susceptibility in the kindling or the pilocarpine model of epilepsy. Behavioral analysis showed a reduced frequency of seizures during physical exercise program. Metabolic, electrophysiological, and immunohistochemical studies have confirmed the positive influence of exercise on epilepsy ([@B9], [@B8]). Although a variety of factors can contribute to such favorable responses, the mechanisms remain poorly understood. Dendritic plasticity, increased neurogenesis, induction of trophic factors and release of neurosteroids are some factors underlying the inhibitory effects of exercise on epileptogenesis. Enrichment of environment has been shown to delay kindling epileptogenesis in rats ([@B11]). It is likely that endogenous neurosteroids may be involved in the neuroprotective effects of exercise and enriched environment. Thus, prevention of loss of interneurons, reduced GABA-A receptor plasticity, and decrease in axonal sprouting could contribute to the disease-modifying effect of exercise and enriched environment.

Despite acute stress-induced seizure protection in animals ([@B150]; [@B184]), patients, and clinicians are not likely to recognize a reduction in seizure frequency associated with stress. It is well known that emotional factors can affect seizure control ([@B223]). In general, stressful events are associated with more frequent epileptiform spikes and seizures ([@B54]). Indeed, stress has been reported to trigger seizure activity in persons with epilepsy ([@B223]; [@B54]). During stressful episodes adrenal hormone levels are expected to fluctuate, possibly affecting epileptogenic events. In agreement with this hypothesis, perinatal stress and elevated steroid levels have been shown accelerate epileptogenesis and lower seizure threshold in various animal models for epilepsy ([@B101]).

Acute stress has anticonvulsant-like effects, while chronic stress is known to induce epileptic seizures. How can such contradictory observations be reconciled? Although the exact pathophysiology of possible seizure facilitation by stress is unknown, there are certainly many neural and endocrine pathways through which stress can alter neuronal excitability and thereby affect seizure susceptibility. The extent of seizure susceptibility during stress might therefore represent a balance between anticonvulsant (e.g., neurosteroids) and proconvulsant factors (e.g., glucocorticoids and CRH). Stress-induced seizures would thus occur when the balance is shifted to favor the proconvulsant factors, surpassing the anticonvulsant action of endogenous neurosteroids ([@B165]). Although little is known regarding proconvulsant factors, stress can increase brain levels of "proconvulsant" sulfated neurosteroids such as pregnenolone sulfate (PS) and dehydroepiandrosterone sulfate (DHEAS; see Role of Neurosteroids in Epileptogenesis). Additionally, repeated episodes of stress and neurosteroid release might lead to a sort of neurosteroid withdrawal-induced hyperexcitable state ([@B176], [@B174]) and could predispose patients to stress-induced seizures. Nevertheless, alleviating the effects of stress by pharmacological interventions may help reduce the epileptogenicity in people with risk factors for epilepsy.

ROLE OF NEUROSTEROIDS IN EPILEPTOGENESIS
========================================

Neurosteroids are steroids synthesized within the brain with unconventional rapid effects on neuronal excitability. It is well known that steroid hormones such as progesterone and DOC can exert anticonvulsant actions ([@B204]; [@B35]). The anticonvulsant properties of progesterone and DOC are predominantly due to their conversion in the brain to neurosteroids allopregnanolone (3α-hydroxy-5α-pregnane-20-one, AP) and allotetrahydrodeoxycorticosterone (THDOC), respectively ([@B161]; [@B172]; **Figure [2](#F2){ref-type="fig"}**). A variety of neurosteroids are known to be synthesized in the brain ([@B17]; [@B113]). The most widely studied are AP, THDOC, and androstanediol. These neurosteroids are produced via sequential A-ring reduction of the steroid hormones by 5α-reductase and 3α-hydroxysteroid-oxidoreductase (3α-HSOR) isoenzymes ([@B167]). The androgenic neurosteroid androstanediol (5α-androstan-3α,17β-diol; **Figure [2](#F2){ref-type="fig"}**) is synthesized from testosterone ([@B163],[@B164]).

In the periphery, the steroid precursors are mainly synthesized in the gonads, adrenal gland, and feto-placental unit, but synthesis of these neurosteroids likely occurs in the brain from cholesterol or from peripherally derived intermediates. Since neurosteroids are highly lipophilic and can readily cross the blood--brain barrier, neurosteroids synthesized in peripheral tissues accumulate in the brain ([@B186]). Recent evidence indicates that neurosteroids are present mainly in principal neurons in many brain regions that are relevant to focal epilepsies, including the hippocampus and neocortex ([@B2]; [@B198]; [@B45]). The biosynthesis of neurosteroids is controlled by the translocator protein (18 kDa; TSPO), formerly called peripheral or mitochondrial benzodiazepine receptor ([@B196], [@B195]). Activation of TSPO by endogenous signals and ligands facilitates the intramitochondrial flux of cholesterol and thereby promotes neurosteroid synthesis. It is suggested that TSPO ligands might be an alternative approach for neurosteroid therapeutics ([@B145]). Currently, synthetic analogs of endogenous neurosteroids are under clinical trial for treatment of epilepsy ([@B186], [@B187]).

POTENTIATION OF PHASIC AND TONIC INHIBITION
-------------------------------------------

Neurosteroids rapidly alter neuronal excitability through direct interaction with GABA-A receptors ([@B75]; [@B128]; [@B74]; [@B62]; [@B156]; [@B94], [@B93]), which are the major receptors for the inhibitory neurotransmitter GABA. Activation of the GABA-A receptor by various ligands leads to an influx of chloride ions and to a hyperpolarization of the membrane that dampens the excitability. Allopregnanolone and other structurally related neurosteroids act as positive allosteric modulators and direct activators of GABA-A receptors (**Figure [3](#F3){ref-type="fig"}**). At low concentrations, neurosteroids potentiate GABA-A receptor currents, whereas at higher concentrations, they directly activate the receptor ([@B74]; [@B184]). Like barbiturates, neurosteroid enhancement of GABA-A receptors occurs through increases in both the channel open frequency and channel open duration ([@B227]; [@B117]; [@B158]). The GABA-A receptor is a pentamer consisting of five subunits that form a chloride channel. Sixteen subunits (α1-6, β1-3, γ1-3, δ, ε, θ, and π subunits) have been identified so far. The GABA site is located at the interface between α and β subunits. Benzodiazepines bind at the interface between α and γ subunits and they interact with subunit combinations α1,2,3,5β2γ2.

![**Neurosteroid modulation of GABA-A receptors in the brain.** Allopregnanolone and related neurosteroids binds and enhances GABA-A receptor-mediated inhibition in the brain. GABA-A receptors are pentameric with five protein subunits that form the chloride ion channel pore. Neurosteroids directly binds to the "neurosteroid binding sites" and potentiate the GABA-gated chloride currents. The neurosteroid binding sites are distinct from sites for GABA, benzodiazepines, and barbiturates. There are two types of GABA-A receptors with different functions. Post-synaptic GABA-A receptors, which are pentameric chloride channels composed of 2α2βγ subunits, mediate the phasic portion of GABAergic inhibition, while extrasynaptic GABA-A receptors, pentamers composed of 2α2βδ subunits, primarily contribute to tonic inhibition in the hippocampus. Neurosteroids activate both synaptic and extrasynaptic receptors and enhance the phasic and tonic inhibition, and thereby promote maximal network inhibition in the brain.](fncel-07-00115-g003){#F3}

Activation of GABA-A receptors produces two forms of inhibition: phasic inhibition generated by the rapid, transient activation of synaptic GABA-A receptors by presynaptic GABA release, and tonic inhibition generated by the persistent activation of extrasynaptic GABA-A receptors, which can detect extracellular GABA (**Figure [3](#F3){ref-type="fig"}**). There are major differences between synaptic and extrasynaptic GABA-A receptors (**Table [3](#T3){ref-type="table"}**). The extrasynaptic GABA-A receptors are distributed within the hippocampus (α4βδ, α5βδ, or α1βδ), neocortex (α4βδ, α5βδ), thalamus (α4βδ), striatum (α4βδ), hypothalamus (α4βδ), and cerebellum (α6βδ). Although GABA activates synaptic (γ2-containing) GABA-A receptors with high-efficacy, GABA activation of the extrasynaptic (δ-containing) GABA-A receptors are limited to low-efficacy activity characterized by minimal desensitization and brief openings. Such tonic currents are particularly evident in dentate granule cells, which play a major role in hippocampus excitability. The high sensitivity of δ-containing receptor channels to neurosteroid modulation may be dependent on the δ-subunit or the low-efficacy channel function that it confers. There is evidence that neurosteroids preferentially enhance low-efficacy GABA-A receptor activity independent of subunit composition ([@B23]).

###### 

An overview of synaptic (αβγ2-containing) and extrasynaptic (αβδ-containing) GABA-A receptors in the brain.

  Synaptic GABA-A receptors                                                                                                   Extrasynaptic GABA-A receptors
  --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Pentameric chloride ion channels                                                                                            Pentameric chloride ion channels
  Contributes to phasic inhibition                                                                                            Contributes to tonic inhibitiion
  Low GABA affinity                                                                                                           High GABA affinity
  High GABA efficacy                                                                                                          Low GABA efficacy
  Pronounced desensitization                                                                                                  Moderate or low desensitization
  Mainly synaptic localization                                                                                                Perisynaptic and extrasynaptic sites
  Benzodiazepine sensitive                                                                                                    Benzodiazepine insensitive
  Potentiated by neurosteroids                                                                                                Highly potentiated by neurosteroids
  Not blocked by low \[Zn^2+^\]                                                                                               Blocked by low \[Zn^2+^\]
  Distributed widely within the brain: cortex, hippocampus, amygdala, limbic structures, thalamus, hypothalamus, cerebellum   Selective distribution in few brain regions: hippocampus, neocortex, thalamus, hypothalamus, cerebellum

The effect of neurosteroids on GABA-A receptors occurs by binding to discrete sites on the receptor--channel complex that are located within the transmembrane domains of the α- and β-subunits ([@B92], [@B94]), which they access by lateral membrane diffusion ([@B32], [@B31]; **Figure [3](#F3){ref-type="fig"}**). The binding sites for neurosteroids are distinct from the recognition sites for GABA, benzodiazepines, and barbiturates ([@B93]). Androgenic neurosteroids such as androstanediol may interact with these sites, and a recent study indicates that this agent is a positive allosteric modulator of GABA-A receptors ([@B175]). Although neurosteroids act on all GABA-A-receptor isoforms, they have large effects on extrasynaptic δ-subunit containing GABA-A receptors that mediate tonic currents ([@B19]; [@B244]). The potentiation of δ-subunit-containing receptors by THDOC and other neurosteroids is selective for channels with low-efficacy gating characteristics marked by brief bursts and channel openings in conditions of both low and high GABA concentrations, and neurosteroids can thereby preferentially increase the efficacy of these receptors based on pharmacokinetics which are not yet fully understood ([@B23]). Neurosteroids therefore markedly enhance the current generated by δ-subunit-containing receptors even in the presence of saturating GABA concentrations. Consequently, GABA-A receptors that contain the δ-subunit are highly sensitive to neurosteroid potentiation and mice lacking δ-subunits show drastically reduced sensitivity to neurosteroids ([@B137]; [@B212]). Tonic current causes a steady inhibition of neurons and reduces their excitability. Neurosteroids therefore could play a role in setting the level of excitability by potentiation of tonic inhibition during seizures when ambient GABA rises ([@B217]).

The pharmacological profile of major neurosteroids is outlined in **Table [4](#T4){ref-type="table"}**. Allopregnanolone-like neurosteroids are powerful antiseizure agents. Exogenously administered neurosteroids exhibit broad-spectrum anticonvulsant effects in diverse rodent seizure models ([@B169]). Neurosteroids protect against seizures induced by GABA-A receptor antagonists, including pentylenetetrazol and bicuculline, and are effective against pilocarpine-induced limbic seizures and seizures in kindled animals ([@B18]; [@B111]; [@B55]; [@B240]; [@B183], [@B186]; [@B104], [@B105]; [@B172]). Like other GABAergic agents, they may exacerbate generalized absence seizures ([@B211]; [@B34]). The potencies of neurosteroids in models where they confer seizure protection vary largely in accordance with their activities as positive allosteric modulators of GABA-A receptors ([@B163],[@B164]; [@B105]). Like other GABAergic agents, neurosteroids are inactive or only weakly active against seizures elicited by maximal electroshock. Neurosteroids are highly active in the 6-Hz model, a better paradigm in which limbic-like seizures are induced by electrical stimulation of lower frequency and longer duration than in the maximal electroshock test ([@B104]). Androstanediol, but not its 3β-epimer, produced a dose-dependent suppression of behavioral and electrographic seizures in the mouse hippocampus kindling ([@B175]). In addition, neurosteroids are also highly effective in suppressing seizures due to withdrawal of GABA-A receptor modulators including neurosteroids and benzodiazepines, as well as other types of agents such as ethanol and cocaine ([@B44]; [@B226]; [@B183]; [@B61]). In contrast to benzodiazepines, where utility in the chronic treatment of epilepsy is limited by tolerance, anticonvulsant tolerance is not evident with neurosteroids ([@B112]; [@B182]), which indicate that neurosteroids are more effective than benzodiazepines for long-term treatment. Novel therapeutic approaches are being developed based on the emerging information on neurosteroid interaction with GABA-A receptors ([@B185]; [@B142]).

###### 

Pharmacological profile of major neurosteroids in animal models.

  Seizure model                          Allopreg-nanolone   THDOC          Andro-stanediol
  -------------------------------------- ------------------- -------------- -----------------
  **Kindling models**                                                       
  Hippocampus kindling                   3.5                 ND             50 (36-64)
  Amygdala kindling                      14 (8--23)          15 (10--30)    ND
  **Chemoconvulsant models**                                                
  Pentylenetetrazol                      12 (10--15)         19 (77--122)   40 (27--60)
  Bicuculline                            12 (10--15)         12 (10--15)    44 (24--81)
  Picrotoxin                             10 (5--19)          10 (5--19)     39 (21--74)
  *N*-Methyl-[D]{.smallcaps}-aspartate   \>40                \>40           \>200
  Kainic acid                            \>40                \>40           \>200
  4-Aminopyridine                        \>40                \>40           \>200
  **Electroshock models**                                                   
  Maximal electroshock                   29 (19--44)         48 (35--66)    ND
  6-Hz stimulation                       14 (10--19)         ND             ND
  **Status epilepticus models**                                             
  Pilocarpine                            7 (4--13)           7 (4--13)      81 (45--133)

The profile of neurosteroids is expressed in terms of ED

50

, which is the dose in mg/kg producing seizure protection in 50% of animals. Values in parentheses are 95% confidence limits. ND, not determined.

ANTIEPILEPTOGENIC ACTIVITY
--------------------------

Neurosteroids may play a role in chronic epilepsy. Neurosteroid modulation of tonic activation of extrasynaptic GABA-A receptors can regulate excitability during epileptogenicity. Given the complex plasticity in GABA-A receptors in epilepsy, it is difficult to predict the functional outcome of altered subunit compositions. A consistent finding from studies that have used various models of chronic epilepsy is that tonic conductances are largely preserved in epileptic brain around the time when synaptic inhibition is reduced ([@B140]; [@B220]; [@B250]). Studies in a status epilepticus model of TLE have shown a striking reduction in δ-subunit containing GABA-A receptors in the dentate gyrus ([@B149]; [@B250]), suggesting that neurosteroid effects on non-synaptic GABA-A receptors may be reduced. There was a compensatory increase in γ2-subunit, so that tonic inhibition is preserved though the efficacy of THDOC in modulating tonic current is decreased. In addition, neurosteroid modulation of synaptic currents is diminished in dentate gyrus granule cells and α4-subunit-containing receptors are expressed at synaptic sites ([@B220]). All of these changes may exacerbate seizures in epileptic animals and reduce the potency but not efficacy of endogenous neurosteroids. The expression of neurosteroidogenic enzymes such as P450scc and 3α-HSOR appears to be elevated in the hippocampus in animals and human subjects affected by TLE ([@B218]; [@B238]; [@B21]). If local neurosteroidogenesis is enhanced, this may in part counteract the epileptogenesis-induced changes.

There is emerging evidence that endogenous neurosteroids play a role in regulating epileptogenesis ([@B50]; [@B20], [@B21], [@B22]; [@B173]; **Figure [4](#F4){ref-type="fig"}**). Using the kindling model, we demonstrated that the development and persistence of limbic epileptogenesis are impaired in mice lacking PRs ([@B179]). To explore mechanisms underlying the observed seizure resistance, we investigated the role of neurosteroids using finasteride, a 5α-reductase inhibitor that blocks the synthesis of progesterone-derived neurosteroids. We determined the rate of rapid kindling in both control animals and those which had received injections of progesterone with or without concurrent finasteride treatment ([@B179]). Progesterone produced a significant delay in the rate of kindling and pretreatment with finasteride blocked progesterone's inhibition of kindling epileptogenesis ([@B181]). These findings are consistent with a contributory role of neurosteroids in limbic epileptogenesis. Thus, it is possible that inhibition of neurosteroids could incite mechanisms that may promote epileptogenesis.

![**Potential molecular mechanisms of neurosteroid interruption of epileptogenesis.** In the brain, allopregnanolone and related neurosteroids may retard epileptogenesis by the interruption of one or more of the pathways leading to development of epilepsy, which generally occurs following an initial precipitating event. Neurosteroids such as allopregnanolone binds to synaptic and extrasynaptic GABA-A receptors and enhances phasic and tonic inhibition within the brain, and thereby may affect epileptogenesis. Other potential mechanisms include modulation of neuroinflammation and neurogenesis in the brain.](fncel-07-00115-g004){#F4}

The P450sc is a critical enzyme for the biosynthesis of neurosteroids (**Figure [2](#F2){ref-type="fig"}**). It is present in neurons, oligodendrocytes, astrocytes, and activated microglia. Following pilocarpine-induced status epilepticus in the rat, the neurosteroidogenic enzyme P450scc is upregulated for several weeks, suggesting that it may be associated with promotion of neurosteroidogenesis ([@B21]). Ordinarily, rats develop spontaneous recurrent seizures following a latent period of similar duration to the period during which P450scc is elevated. The role of neurosteroids in delaying seizure onset in the pilocarpine model is confirmed using finasteride, which can exacerbate seizures by inhibition of neurosteroid synthesis. Inhibiting neurosteroid synthesis with finasteride accelerated the onset of spontaneous recurrent seizures ([@B20]), suggesting that endogenous neurosteroids play a role in restraining epileptogenesis, or at least act to inhibit the expression of seizures.

The development of epilepsy is linked to complex alterations in neuroplastic mechanisms. Dysregulation of neurosteroid synthesis may also play a role. This premise is being tested in various epileptogenic models ([@B179]). We investigated the role of the prototype endogenous neurosteroid allopregnanolone in controlling limbic epileptogenesis. Treatment with finasteride, a neurosteroid synthesis inhibitor, resulted in a significant increase in epileptogenesis in the hippocampus kindling model ([@B159]). Exogenous administration of allopregnanolone, at doses that produce levels similar to gonadotropins, markedly inhibited epileptogenesis. In female epilepsy rats, finasteride treatment exacerbates seizure frequency ([@B118]). Neurosteroid-mediated increase in tonic inhibition in the hippocampus could inhibit the spread of the seizure discharge from the hippocampal focus and thereby suppress the rate of development of behavioral kindled seizure activity without affecting the focal electrographic discharges (**Figure [4](#F4){ref-type="fig"}**). The exact mechanisms are unclear. Increased tonic inhibition by allopregnanolone is shown to impair the NMDA (*N*-methyl-[D]{.smallcaps}-aspartate) receptor-mediated excitability in the hippocampus ([@B206]). It is likely that such a mechanism may underlie the progesterone's disease-modifying effects in the kindling model. Based on these pilot studies, it is suggested that augmentation of neurosteroid synthesis may represent a unique strategy for preventing or retarding epileptogenesis.

PROCONVULSANT AND EPILEPTOGENIC ACTIVITY
----------------------------------------

Neurosteroids that are sulfated at C3 have inhibitory actions on GABA-A receptors ([@B147]). PS and DHEAS block GABA-A receptors at low micromolar concentrations ([@B126]). These "sulfated steroids" act as non-competitive antagonists of the GABA-A receptor by interacting with a site that is distinct from that of neurosteroids such as allopregnanolone and THDOC ([@B129]; [@B127]; [@B147]). The steroid negative modulatory action on GABA-A receptors occurs through a reduction in channel opening frequency, although the precise mechanism of block is not well understood ([@B136]; [@B5]). PS has been shown to possess agonistic actions on NMDA receptors ([@B247]) and presynaptic sites ([@B141]). Given their abundance in brain, it seems reasonable that PS and DHEAS could function as endogenous neuromodulators. In contrast to allopregnanolone, sulfated neurosteroids PS and DHEAS exert proconvulsant or convulsant actions ([@B177]; [@B110]). Direct injection of PS to rodent brain elicits seizures which increase in severity and frequency with time and eventually progress to status epilepticus, tonic hindlimb extension, and death of the animals ([@B110]; [@B243]). However, systemic administration of PS does not induce overt seizure activity ([@B110]). The pharmacology of PS seizures is poorly understood, but both clonazepam and allopregnanolone can effectively protect against PS-induced seizure activity ([@B110]). The proconvulsant effect of DHEAS is reduced by progesterone, an intermediate precursor of neurosteroid synthesis. Moreover, exogenous application or endogenous stimulation of DHEAS modulates hippocampal GABA inhibition possibly by entraining hippocampal neurons to theta rhythm ([@B214]), suggesting a potential physiological relevance of the proconvulsant effects of DHEAS in animals.

GENDER DIFFERENCES IN EPILEPSY AND NEUROSTEROIDS
================================================

Epilepsy shows sex differences in incidence, progression, and severity, as well as in responsiveness to therapy. The incidence of epilepsy is generally higher in males than in females. More women than men are diagnosed with idiopathic generalized epilepsy, but localization-related symptomatic epilepsies are more frequent in men, and cryptogenic localization-related epilepsies are more frequent in women ([@B76]; [@B33]). Sex differences have been described in patients with TLE, with respect to distinct regional distribution of brain dysfunction during interictal periods as well as to the extent of neuronal damage. Women tend to have less structural atrophy than men, regardless of the seizure rate. During brain development, sex hormones have organizational effects leading to permanent differences between males and females in distinct brain regions ([@B232]). However, the precise mechanisms underlying the sex-dependent differentiation of the specific neuronal circuits, particularly brain regions involved in seizure control, are not clear. Many factors are involved in determining sex differences in seizure susceptibility, including the presence of sexual dimorphism in brain structures involved in seizure generation and control, in regional connectivity, sensitivity of neurotransmitter systems, receptor distribution, and dependence on hormonal milieu and on changes in sex hormone levels during the life span.

Neurosteroids exhibit a strong gender differences in their pharmacological effects with more potency in females than males ([@B168]). Steroid hormones such as progesterone and testosterone play a key role in the gender-related differences in susceptibility to seizures. However, the precise mechanism underlying such sexual dimorphism is obscure. Many of the biological actions of steroid hormones are mediated through intracellular receptors. Studies have suggested that these sex differences in seizure sensitivity are due to gender-specific distribution of steroid hormones or other sexually dimorphic characteristics in specific brain areas relevant to epilepsy. For example, estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats, suggesting that the effects of estradiol on seizure threshold and damage may be determined by sex-related differences in the hormonal environment. Neurosteroids may play a key role in gender-related differences in seizure susceptibility ([@B168]). Both progesterone and allopregnanolone protect against experimental seizures in both male and female mice lacking PRs ([@B172]). However, female mice exhibit significantly enhanced sensitivity to the protective activity of allopregnanolone as compared to males. In the pilocarpine seizure test, androstanediol has similar increased potency in female mice, which is not related to differences in pharmacokinetics of this neurosteroid. These results underscore the possible role of endogenous neurosteroids in gender-related differences in seizure susceptibility and protection.

POTENTIAL SIDE EFFECTS OF NEUROSTEROIDS
=======================================

Steroid hormones such as progesterone and DOC have long been known to have sedative, anesthetic, and antiseizure properties ([@B3]; [@B71]; [@B69]). Studies during the past three decades have uncovered that neurosteroids mediate such rapid effects of steroid hormones in the brain ([@B172], [@B180]). Unlike steroid hormones, the acute effects of neurosteroids are not related to interactions with classical steroid hormone receptors that regulate gene transcription. Moreover, neurosteroids are not themselves active at intracellular steroid receptors. They modulate brain excitability primarily by interaction with neuronal membrane receptors and ion channels, principally GABA-A receptors. Therefore, like other GABAergic agents, neurosteroids have sedative and anxiolytic properties ([@B161]). At high doses, neurosteroids cause anesthetic effects. This feature is exemplified with alphaxolone, which was introduced as intravenous anesthetic in 1970s. It was withdrawn later from the market due to toxicity of the solvent used for formulation of this synthetic neurosteroid. Although natural neurosteroids can be used for therapeutic purpose in patients with epilepsy, certain obstacles prevent the clinical use of endogenous neurosteroids. First, natural neurosteroids such as allopregnanolone have low bioavailability because they are rapidly inactivated and eliminated by glucuronide or sulfate conjugation at the 3α-hydroxyl group. Secondly, the 3α-hydroxyl group of allopregnanolone may undergo oxidation to the ketone, restoring activity at steroid hormone receptors ([@B197]). Synthetic neurosteroids, which are devoid of such hormonal actions, could provide a rational alternative approach to therapy ([@B178]). Recently, a number of synthetic analogs of allopregnanolone and other neurosteroids are tested in animals and human trials. Ganaxolone, the 3β-methyl analog of allopregnanolone, is a synthetic neurosteroid analog that overcomes these limitations ([@B30]). Results from the clinical trials of ganaxolone demonstrated a benign side effect profile ([@B188]). More than 900 subjects (adults and children) have received this neurosteroid in Phase 1 and 2 trials. Overall, the drug is safe and well tolerated. The most common side effect is reversible dose-related sedation. Other adverse events reported by few subjects include dizziness, fatigue, and somnolence, which indicate its GABAergic effects.

CONCLUSION
==========

The major part of the pathophysiology of epilepsy is epileptogenesis, whereby a normal brain becomes progressively epileptic because of injury factors. Despite increased scientific awareness, there is a large gap in our understanding of epileptogenesis and many questions remain unanswered regarding the cellular and molecular mechanisms underlying the "irreversible conversion" of a normal brain into epileptic brain predisposed to recurrent seizures. Such gaps in our knowledge about epilepsy's risk factors, comorbidities, and outcomes limit the ability of clinical programs to prevent epilepsy and its consequences. Since the Curing Epilepsy conference in 2000, there has been more focused research on optimizing approaches in preventing epilepsy and there is emphasis on several translation models. Reduction in neuroinflammation and neurodegeneration is a widely targeted approach for curing epilepsy. Despite intense search for drugs that interrupt epileptogenesis, presently there is no FDA-approved drug available for prevention of epilepsy development in patients at risk. It is essential to find a lead target, such as a receptor or signaling pathway that is crucial for the progression of epileptogenesis that can be disrupted by pharmacological agents to prevent or retard epilepsy.

A variety of pharmacological agents have been tested in animal models of epileptogenesis and in clinical trials in patients with a risk factor for epilepsy. However, the outcomes are not highly promising. The pipeline of new drugs for clinical development is very limited. A summary of agents that are currently in development for epilepsy is listed in **Table [5](#T5){ref-type="table"}**. Steroid hormones, especially corticosteroids, estrogen, and progesterone play an important role in epilepsy. Repetitive stress and corticosteroids increases the risk of epilepsy. There is emerging evidence that neurosteroids may play a role in limbic epileptogenesis. Neurosteroids that enhance the GABAergic inhibition within the brain are potent anticonvulsants and they regulate neural excitability networks by enhancing the phasic and tonic inhibition in the hippocampus, a critical region involved in the TLE. Tonic inhibition is therefore an attractive target for antiepileptogenic drugs (**Figure [4](#F4){ref-type="fig"}**). The effects of stress and hormonal changes on neuronal excitability are most likely mediated by neurosteroids. Therefore, menstrual, gonadal, and stress-related fluctuations in neurosteroids or dysfunction in their synthesis can alter epileptogenesis in people at risk for epilepsy. As pleotropic agents, steroid hormones can modify, interrupt or reverse the epileptogenic process, such as cell loss, neuroinflammation, neurogenesis, astrogliosis, and axonal sprouting.

###### 

Pipeline of new drugs for epilepsy under development.

  Agent                                            Pharmacological profile
  ------------------------------------------------ ----------------------------------------------------------------------------------
  BGG492 (Novartis)                                A competitive AMPA/kainate receptor antagonist
  Brivaracetam (UCB)                               A novel high-affinity synaptic vesicle protein 2A (SV2A) ligand
  CPP-115 (Catalyst)                               A GABA transaminase inhibitor (vigabatrin derivative)
  ICA-105665 (Pfizer)                              A highly selective opener of neuronal Kv7 (KCNQ) potassium channels
  T2000 (Taro)                                     A non-sedating barbiturate (prodrug of diphenylbarbituric acid)
  Tonabersat (Upsher-Smith)                        A novel mechanism of uncoupling of neuronal gap junctions
  UCB-0942 (UCB)                                   A new pre-and post-synaptic inhibitor
  VX765 (Vertex)                                   A selective inhibitor of interleukin converting enzyme
  YKP3089 (SK Life)                                Novel mechanism of action
  2-Deoxy-[D]{.smallcaps}-glucose (NeuroGenomeX)   A glucose analog and glycolytic inhibitor
  Ganaxolone (Marinus)                             A synthetic neurosteroid and GABA-A receptor modulator
  Imepitoin (BI)                                   A low-affinity partial agonist at the benzodiazepine site of the GABA-A receptor
  NAX 810-2 (NeuroAdjuvants)                       Galanin receptor GalR1 and GalR2 agonist
  Valnoctamide (Hebrew Univ)                       Valproic acid second generation derivative
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